VIDEO: GLOBE Final Rule with Tim Wright, Genesis Research Group

On October 2, 2026, CMS finalized its 585-page GLOBE rule. So, what do manufacturers need to know?

In this must-watch update, Tim Wright (Genesis Research Group) joins our Editor, Laura Dormer, to unpack what has changed from the proposed model and what the final rule could mean in practice.

From new drug exclusions and the interaction with GENEROUS to substantially lower projected savings, Tim examines the key details and what they could mean as GLOBE moves towards implementation in 2027.

Speaker

Tim Wright
Executive Vice President, Access and Pricing, Genesis Research Group

Tim Wright leads the Access & Pricing division at Genesis Research Group. An economist and health economist, Tim has 30 years of experience in the biopharma sector, including 18 years in executive positions in strategic consulting firms and 12 years in global EU and UK roles in industry. In consulting, Tim has provided strategic leadership in over 1000 engagements with small biotechs to top-five pharma and across all therapy areas. Within the industry, Tim was responsible for global pricing and access strategy for two mega-brands and the CV, respiratory, infection and inflammation early asset portfolio at AstraZeneca. He is former Head of HEOR at Janssen Cilag UK, and brings experience from EU Pricing for Allergan and his time as a clinical scientist at Astra.

The views and opinions expressed in this feature are those of the interviewee and do not necessarily reflect the views or positions of Genesis Research Group and its affiliates. The information provided is for general information purposes only and should not be taken as professional advice.

The opinions expressed in this feature are those of the author and do not necessarily reflect the views of The Evidence Base® or Becaris Publishing Ltd.

Sponsorship for this Video was provided by Genesis Research Group.